Oruka Therapeutics, Inc.
ORKA
$41.35
-$0.40-0.96%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 32.71% | 17.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.96% | 19.97% | |||
| Operating Income | -0.96% | -19.97% | |||
| Income Before Tax | 2.29% | -23.21% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 2.29% | -23.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.29% | -23.21% | |||
| EBIT | -0.96% | -19.97% | |||
| EBITDA | -0.93% | -19.98% | |||
| EPS Basic | 17.74% | -18.84% | |||
| Normalized Basic EPS | 21.12% | -17.68% | |||
| EPS Diluted | 17.74% | -18.84% | |||
| Normalized Diluted EPS | 21.12% | -17.68% | |||
| Average Basic Shares Outstanding | 23.87% | 4.68% | |||
| Average Diluted Shares Outstanding | 23.87% | 4.68% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||